Inna Y Gong1, Matthew C Cheung1,2,3, Stephanie Read4, Yingbo Na2,4, Iliana C Lega1,2,4, Lorraine L Lipscombe5,6,7. 1. Department of Medicine, University of Toronto, Toronto, ON, Canada. 2. ICES, Toronto, Ontario, Canada. 3. Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada. 4. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 5. Department of Medicine, University of Toronto, Toronto, ON, Canada. Lorraine.Lipscombe@wchospital.ca. 6. ICES, Toronto, Ontario, Canada. Lorraine.Lipscombe@wchospital.ca. 7. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. Lorraine.Lipscombe@wchospital.ca.
Abstract
AIMS/HYPOTHESIS: Contemporary data for the association of diabetes with haematological malignancies are lacking. We evaluated the risk of developing haematological malignancies and subsequent mortality in individuals with diabetes compared with those without diabetes. METHODS: We conducted a population-based observational study using healthcare databases from Ontario, Canada. All Ontario residents 30 years of age or older free of cancer and diabetes between 1 January 1996 and 31 December 2015 were eligible for inclusion. Using Cox regression analyses, we explored the association between diabetes and the risk and mortality of haematological malignancies (leukaemia, lymphoma, multiple myeloma). The impact of timing on associations was evaluated with analyses stratified by time since diabetes diagnosis (<3 months, 3 months to 1 year, ≥1 year). RESULTS: We identified 1,003,276 individuals with diabetes and age and sex matched these to 2,006,552 individuals without diabetes. Compared with individuals without diabetes, those with diabetes had a modest but significantly higher risk of a haematological malignancy (adjusted HR 1.10 [95% CI 1.08, 1.12] p < 0.0001). This association persisted across all time periods since diabetes diagnosis. Among those with haematological malignancies, diabetes was associated with a higher all-cause mortality (HR 1.36 [95% CI 1.31, 1.41] p < 0.0001) compared with no diabetes, as well as cause-specific mortality. CONCLUSIONS/ INTERPRETATION: Diabetes is associated with a higher risk of haematological malignancies and is an independent risk factor of all-cause and cause-specific mortality. Greater efforts for lifestyle modification may not only reduce diabetes burden and its complications but may also potentially lower risk of malignancy and mortality. Graphical abstract.
AIMS/HYPOTHESIS: Contemporary data for the association of diabetes with haematological malignancies are lacking. We evaluated the risk of developing haematological malignancies and subsequent mortality in individuals with diabetes compared with those without diabetes. METHODS: We conducted a population-based observational study using healthcare databases from Ontario, Canada. All Ontario residents 30 years of age or older free of cancer and diabetes between 1 January 1996 and 31 December 2015 were eligible for inclusion. Using Cox regression analyses, we explored the association between diabetes and the risk and mortality of haematological malignancies (leukaemia, lymphoma, multiple myeloma). The impact of timing on associations was evaluated with analyses stratified by time since diabetes diagnosis (<3 months, 3 months to 1 year, ≥1 year). RESULTS: We identified 1,003,276 individuals with diabetes and age and sex matched these to 2,006,552 individuals without diabetes. Compared with individuals without diabetes, those with diabetes had a modest but significantly higher risk of a haematological malignancy (adjusted HR 1.10 [95% CI 1.08, 1.12] p < 0.0001). This association persisted across all time periods since diabetes diagnosis. Among those with haematological malignancies, diabetes was associated with a higher all-cause mortality (HR 1.36 [95% CI 1.31, 1.41] p < 0.0001) compared with no diabetes, as well as cause-specific mortality. CONCLUSIONS/ INTERPRETATION: Diabetes is associated with a higher risk of haematological malignancies and is an independent risk factor of all-cause and cause-specific mortality. Greater efforts for lifestyle modification may not only reduce diabetes burden and its complications but may also potentially lower risk of malignancy and mortality. Graphical abstract.
Authors: Karin Ekström Smedby; Henrik Hjalgrim; Johan Askling; Ellen T Chang; Henrik Gregersen; Anna Porwit-MacDonald; Christer Sundström; Måns Akerman; Mads Melbye; Bengt Glimelius; Hans-Olov Adami Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: Eric A Engels; James R Cerhan; Martha S Linet; Wendy Cozen; Joanne S Colt; Scott Davis; Gloria Gridley; Richard K Severson; Patricia Hartge Journal: Am J Epidemiol Date: 2005-10-26 Impact factor: 4.897
Authors: Lorenzo Scappaticcio; Maria Ida Maiorino; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2016-12-31 Impact factor: 3.633
Authors: Iliana C Lega; Andrew S Wilton; Peter C Austin; Hadas D Fischer; Jeffrey A Johnson; Lorraine L Lipscombe Journal: Cancer Date: 2016-07-11 Impact factor: 6.860
Authors: Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz Journal: Blood Date: 2012-10-16 Impact factor: 22.113
Authors: C Brooke Steele; Cheryll C Thomas; S Jane Henley; Greta M Massetti; Deborah A Galuska; Tanya Agurs-Collins; Mary Puckett; Lisa C Richardson Journal: MMWR Morb Mortal Wkly Rep Date: 2017-10-03 Impact factor: 17.586